Reply to “Prognostic factors in neurofibromatosis type 1‐associated malignant peripheral nerve sheath tumors: Clinical implications beyond NF1 status”
Cancer · 15.04.2026 · 132 (8)
DOI: 10.1002/cncr.70397 ↗Kurz gefasst
Leserbrief in der Zeitschrift Cancer, online erschienen am 09.04.2026. Verfasst von Rachel E Aubrey und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada. Die Arbeit nennt 3 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Division of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
- University of Toronto, Toronto, Ontario, Canada.
- Department of Radiation Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
ORCID-Profile: Rachel E Aubrey
Zitieren
APA
Aubrey, R. E., Soroka, H. P., Gupta, A. A., & Shultz, D. B. (2026). Reply to “Prognostic factors in neurofibromatosis type 1‐associated malignant peripheral nerve sheath tumors: Clinical implications beyond NF1 status”. Cancer, 132(8). https://doi.org/10.1002/cncr.70397
Vancouver
Aubrey RE, Soroka HP, Gupta AA, Shultz DB. Reply to “Prognostic factors in neurofibromatosis type 1‐associated malignant peripheral nerve sheath tumors: Clinical implications beyond NF1 status”. Cancer. 2026;132(8). doi:10.1002/cncr.70397
BibTeX
@article{Aubrey2026,
author = {Aubrey, Rachel E and Soroka, Hagit Peretz and Gupta, Abha A and Shultz, David B},
title = {Reply to “Prognostic factors in neurofibromatosis type 1‐associated malignant peripheral nerve sheath tumors: Clinical implications beyond NF1 status”},
journal = {Cancer},
year = {2026},
volume = {132},
number = {8},
doi = {10.1002/cncr.70397}
}
EUVIMED